agilon health financials
$78.15−1.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $5.93B | $6.06B | $4.32B | $2.39B | $1.52B |
| Gross profit | -$160.0M | $4.8M | $69.7M | $111.4M | $65.7M |
| Gross margin | −2.7% | 0.1% | 1.6% | 4.7% | 4.3% |
| Operating income | -$463.2M | -$292.1M | -$232.1M | -$105.4M | -$372.2M |
| Net income | -$391.3M | -$260.2M | -$262.6M | -$106.6M | -$406.5M |
| Net margin | −6.6% | −4.3% | −6.1% | −4.5% | −26.7% |
| Diluted EPS | $-23.75 | $-15.75 | $-16.00 | $-6.50 | $-27.25 |
| EBITDA | -$398.6M | -$264.1M | -$212.0M | -$91.6M | -$357.6M |
| Operating cash flow | -$105.8M | -$57.8M | -$156.2M | -$130.8M | -$148.2M |
| Free cash flow | -$119.0M | -$71.0M | -$172.0M | -$146.2M | -$154.7M |
| Diluted shares | 16.6M | 16.4M | 16.4M | 16.3M | 14.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $173.7M | $188.2M | $107.6M | $465.3M | $1.04B |
| Short-term investments | $111.4M | $211.7M | $380.8M | $411.9M | $0.00 |
| Total debt | $35.0M | $34.9M | $32.3M | $43.5M | $48.4M |
| Total assets | $1.27B | $1.73B | $1.74B | $1.70B | $1.59B |
| Total liabilities | $1.14B | $1.26B | $1.08B | $656.9M | $494.7M |
| Shareholders' equity | $126.7M | $471.0M | $661.0M | $1.04B | $1.09B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology